How Are Responsibilities of Authorized Representatives for Overseas Medical Device Registration Divided?

Professional Answer

The division of responsibilities for an authorized representative in overseas medical device registration depends on the regulatory framework of the target country. In the European Union, under the MDR, the authorized representative (EC REP) is legally responsible for post-market surveillance, adverse event reporting, and communication with competent authorities. In China, the domestic agent designated by the overseas applicant must assist with registration, handle adverse events, and cooperate with regulatory inspections. For GHWP member countries (e.g., ASEAN, Middle East), the authorized representative typically handles local registration applications, technical file maintenance, label review, and post-market compliance. Manufacturers must first determine if their product qualifies as a medical device, then assess risk classification and registration pathway. Essential documents include ISO 13485 certificate, risk management report, clinical evaluation data, and product labeling. Common risks include the representative lacking technical capability to report changes in time, unclear control over certificates, and undefined renewal responsibilities leading to certificate expiry. Clear agreements defining scope of responsibilities, data sharing, and fee arrangements are critical, along with a dedicated contact person. Post-market monitoring of regulatory updates and cooperation in audits are necessary to avoid market access issues due to agent errors.

Regulatory Framework and Responsibilities

EU MDR

Under the EU Medical Device Regulation (MDR), the authorized representative (EC REP) must be established in the EU and is responsible for post-market surveillance, adverse event reporting, communication with competent authorities, and ensuring that the manufacturer complies with obligations. The manufacturer remains the primary responsible party, but the EC REP bears specific legal liabilities.

China NMPA

For China, overseas manufacturers must designate a domestic agent (registered in China with a business license) to assist with NMPA registration, handle adverse event reporting, and cooperate with on-site inspections. The agent acts as a liaison but does not replace the manufacturer's ultimate responsibility.

GHWP Member Countries

In GHWP countries (e.g., ASEAN, Saudi Arabia, Brazil), the authorized representative typically manages local registration applications, maintains technical files in local language, reviews labels for compliance, and handles post-market obligations. The representative must hold local business permits and be familiar with national regulations.

Key Requirements and Common Risks

Required Documents

• Technical File: Including performance validation, risk management (ISO 14971), and clinical evaluation.
• Quality Management System Certificate: ISO 13485 or MDSAP.
• Labeling and Instructions for Use: Translated into local official languages.
• Authorized Representative Agreement: Clearly defining scope of responsibilities, data sharing, and fees.
• Post-Market Surveillance Plan and reporting templates.
• Change Management Procedures to ensure the representative is notified of product changes.
• Adverse Event Reporting Process outlining collaboration between manufacturer and representative.
• Certificate Renewal Responsibility Assignment.

Common Mistakes

• Treating registration as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility.
• Directly translating NMPA submissions without restructuring evidence according to target market pathways.
• Having too many model variants without sufficient test reports, clinical evidence, or label coverage.
• Selecting a local agent based solely on sales capability, neglecting regulatory responsibilities, certificate control, and post-market duties.
• Inconsistent claims across labels, IFU, promotional materials, and registration documents, leading to deficiencies or compliance risks.
• Failing to plan for multi-country document reuse, resulting in repetitive work, higher costs, and longer timelines.

Preparation Checklist

• Compile product list, model matrix, and intended use statements.
• Review existing registrations (NMPA, CE, FDA) for reusability.
• Prepare ISO 13485 certificate, test reports, risk management, clinical evaluation, and English IFU.
• Confirm local representative's responsibilities, fees, certificate control, and exit mechanisms.
• Create a gap assessment table for each target country, identifying needs for additional tests, translations, notarizations, or declarations.

Regulatory Interpretation and Business Impact

A common misconception is that an authorized representative can handle all registration tasks; in reality, regulators hold the manufacturer as the primary responsible party. Manufacturers should review target country requirements early, create a responsibility matrix, and avoid verbal agreements. International certifications like CE, ISO 13485, and MDSAP can be reused, but labeling, IFU, and clinical evaluation require local adaptation. Control over certificates is critical—agreements must specify ownership to prevent market access issues if the representative changes. For multi-country registrations, it is advisable to engage a representative with multinational branches to standardize processes and reduce rework. Post-market, establish annual review mechanisms to ensure the representative fulfills ongoing obligations.

Frequently Asked Follow-Up Questions

What if the authorized representative cannot fulfill obligations? The manufacturer must immediately find a replacement and notify the regulatory authority. During transition, the manufacturer directly assumes post-market surveillance and reporting duties, or the product may be suspended. Include exit mechanisms and a backup representative list in the agreement.

Can one representative company be used for multiple countries? Some large representatives have subsidiaries in multiple countries that can provide one-stop service, but each local entity must be independently licensed and comply with local laws. For countries like Saudi Arabia or China, a local legal entity is mandatory; a representative from another country cannot sign.

Can the authorized representative delegate technical file writing to a third party? Usually allowed, but the representative and manufacturer remain ultimately responsible. If outsourcing, sign a confidentiality agreement and ensure quality. It is recommended that the manufacturer leads file creation while the representative handles submission and communication.

Implementation Recommendations

Break down the question into five tasks: regulatory assessment, document preparation, evidence reuse, localization, and post-market maintenance. This helps identify gaps early and align sales, R&D, quality, and regulatory teams on target country requirements. For simultaneous multi-market entry, create a core technical file first, then add country-specific authorizations, labels, languages, forms, and local agent documents. Efficiency depends on a unified document framework, not the speed of individual submissions. Confirm product classification under target country regulations, determine risk class and pathway, ensure technical files, QMS, and clinical evidence are consistent, clarify control of certificates and local representative responsibilities, and establish post-market change, renewal, and vigilance processes.